CFA
KERX

CT Financial Advisors’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

CT Financial Advisors’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		$6.38K Hold
1,035
– – ﹤0.01% 488
2016
Q4 		$6.07K Hold
1,035
– – ﹤0.01% 493
2016
Q3 		$5.5K Hold
1,035
– – ﹤0.01% 496
2016
Q2 		$6.85K Hold
1,035
– – ﹤0.01% 473
2016
Q1 		$4.83K Hold
1,035
– – ﹤0.01% 512
2015
Q4 		$5.23K Hold
1,035
– – ﹤0.01% 511
2015
Q3 		$3.64K Hold
1,035
– – ﹤0.01% 544
2015
Q2 		$10.3K Sell
1,035
-800
-44% -$8.58K 0.01% 469
2015
Q1 		$23.4K Hold
1,835
– – 0.01% 373
2014
Q4 		$26K Buy
+1,835
New +$28.4K 0.02% 296
2014
Q1 		$23.4K Buy
+1,835
New +$27.7K 0.01% 373

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
CLM
ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return

CT Financial Advisors's KERX Position: Q1 2017 in Review

CT Financial Advisors held its Keryx Biopharmaceuticals Inc (KERX) position steady in Q1 2017 at 1,035 shares worth $6.38K. The position accounts for ﹤0.01% of the portfolio, ranked #488.

CT Financial Advisors first reported a position in KERX in Q1 2014 and has held it in 11 quarters since. The position peaked at $26K in Q4 2014. 119 funds tracked by Wall St. Rank hold KERX as of Q1 2017.

  • CT Financial Advisors held 1,035 shares of Keryx Biopharmaceuticals Inc worth $6.38K as of Q1 2017.
  • CT Financial Advisors left its Keryx Biopharmaceuticals Inc share count unchanged in Q1 2017.
  • Keryx Biopharmaceuticals Inc made up ﹤0.01% of CT Financial Advisors's portfolio in Q1 2017, its #488 holding.
  • CT Financial Advisors first reported a position in Keryx Biopharmaceuticals Inc in Q1 2014 and has held it in 11 quarters since.
  • CT Financial Advisors's Keryx Biopharmaceuticals Inc position peaked at $26K in Q4 2014.
  • 119 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q1 2017.

Based on CT Financial Advisors's 13F filing for Q1 2017, filed 7 Apr 2017.